CL2011001850A1 - Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. - Google Patents

Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.

Info

Publication number
CL2011001850A1
CL2011001850A1 CL2011001850A CL2011001850A CL2011001850A1 CL 2011001850 A1 CL2011001850 A1 CL 2011001850A1 CL 2011001850 A CL2011001850 A CL 2011001850A CL 2011001850 A CL2011001850 A CL 2011001850A CL 2011001850 A1 CL2011001850 A1 CL 2011001850A1
Authority
CL
Chile
Prior art keywords
compound
cancers
treatment
pharmaceutical composition
colon cancer
Prior art date
Application number
CL2011001850A
Other languages
English (en)
Inventor
Edmundo J Lavoie
Beverly Teicher
Steven Schmid
Original Assignee
Genzyme Corp
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42077313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001850(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Univ Rutgers filed Critical Genzyme Corp
Publication of CL2011001850A1 publication Critical patent/CL2011001850A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

.
CL2011001850A 2009-01-30 2011-07-29 Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto. CL2011001850A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14888109P 2009-01-30 2009-01-30
US24087309P 2009-09-09 2009-09-09

Publications (1)

Publication Number Publication Date
CL2011001850A1 true CL2011001850A1 (es) 2012-08-31

Family

ID=42077313

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001850A CL2011001850A1 (es) 2009-01-30 2011-07-29 Uso de un compuesto nitrogenado heterociclico sustituido para el tratamiento de cánceres tales como cáncer de colon o mieloma múltiple;composición farmacéutica que comprende al compuesto.

Country Status (19)

Country Link
US (1) US20120004235A1 (es)
EP (1) EP2391364A1 (es)
JP (1) JP2012516849A (es)
KR (1) KR20110122141A (es)
CN (1) CN102395368A (es)
AR (1) AR075346A1 (es)
AU (1) AU2010208042A1 (es)
BR (1) BRPI1008155A2 (es)
CA (1) CA2749204A1 (es)
CL (1) CL2011001850A1 (es)
CO (1) CO6410302A2 (es)
EA (1) EA201101140A1 (es)
IL (1) IL213919A0 (es)
MX (1) MX2011008069A (es)
NZ (1) NZ593849A (es)
PE (1) PE20120112A1 (es)
SG (1) SG173454A1 (es)
TW (1) TW201038578A (es)
WO (1) WO2010088544A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5773888B2 (ja) * 2009-03-06 2015-09-02 ラットガーズ，ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ［ｉ］フェナントリジン誘導体
EP3442979A4 (en) 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
CN108690034A (zh) * 2018-01-12 2018-10-23 兰州大学 一种氟化苯并萘啶酮类衍生物、制备方法及用途
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2001032631A2 (en) 1999-10-29 2001-05-10 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
ATE405568T1 (de) * 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
AU2002363658B2 (en) * 2001-11-14 2008-09-11 Rutgers, The State University Solubilized topoisomerase poisons
AU2003268075A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6989387B2 (en) * 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents

Also Published As

Publication number Publication date
CO6410302A2 (es) 2012-03-30
TW201038578A (en) 2010-11-01
US20120004235A1 (en) 2012-01-05
CN102395368A (zh) 2012-03-28
BRPI1008155A2 (pt) 2016-03-08
KR20110122141A (ko) 2011-11-09
NZ593849A (en) 2014-02-28
AR075346A1 (es) 2011-03-23
PE20120112A1 (es) 2012-02-27
WO2010088544A8 (en) 2011-07-28
EP2391364A1 (en) 2011-12-07
EA201101140A1 (ru) 2012-03-30
AU2010208042A1 (en) 2011-07-21
MX2011008069A (es) 2011-09-06
CA2749204A1 (en) 2010-08-05
IL213919A0 (en) 2011-07-31
WO2010088544A1 (en) 2010-08-05
SG173454A1 (en) 2011-09-29
JP2012516849A (ja) 2012-07-26

Similar Documents

Publication Publication Date Title
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
CL2012001627A1 (es) Compuestos derivados de 1,3-tiazol-fenilaminopirimidinas, inhibidores de syk; composición farmacéutica; y su uso para el tratamiento de la artritis reumatoide y cancer.
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
EA201171367A1 (ru) Винилиндазолильные соединения
PH12015500263A1 (en) New bicyclic derivatives
PA8740901A1 (es) Compuestos organicos
CL2012000324A1 (es) Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
MX2012012527A (es) Compuestos quimicos.
MX339192B (es) Compuestos heterociclicos utiles para inhibicion de cinasa.
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
PE20151417A1 (es) Inhibidores de histona desmetilasa
CL2010000320A1 (es) Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer.
CO6480975A2 (es) Mimetico de smac
CL2015002591A1 (es) Entidades químicas.
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CO6341625A2 (es) Derivados de indol como agentes anticáncer
BR112012023836A2 (pt) composto tricíclicos e inibidores de pbk contendo os mesmos
AR067769A1 (es) Derivado de ditiazol para el tratamiento del cancer